HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CBD Beauty Sprouting Up Left And Right, From Skin Care To Toothpaste And Dirty Grass Perfume

Executive Summary

Despite current risks in an uncertain legal environment, the opportunity for CBD-infused cosmetics at a time of rocketing interest in all things cannabis is proving too great for many companies to resist.

You may also be interested in...



CBD Beauty Claims Based On Third-Party Studies Could Be Litigation Targets – Venable Attorney

There’s a growing body of scientific evidence linking cannabidiol to benefits of interest to beauty industry players, but if a company’s CBD ingredient differs from the substance studied, that could be grounds for a false-advertising complaint. Venable partner Todd Halpern discusses.

FDA Road To Decision On Expanding CBD Uses Starts With Weighing Impact On Existing And Future Use As Drug

At public hearing, FDA officials starting with acting Commissioner Sharpless emphasized CBD is approved only as a drug and deciding on allowing its use in any other type of FDA-regulated product will be done with potential impact on drug development foremost in agency's thinking. Also apparent from questions 12-member panel of FDA officials asked was a potential regulatory pathway for clearing hemp and CBD as dietary ingredients will require resolving concerns about the substances' dose or concentration levels and establishing ingredient identity standards.

Interested In Using CBD Or Probiotics In Cosmetics? Ask Yourself Why – FDA’s Linda Katz

The answer to the ‘why’ question can help clarify whether a company is marketing a cosmetic or an unapproved drug, FDA’s cosmetics office director advised attendees at ICMAD’s 38th annual regulatory workshop in New York.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148881

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel